TONIX PHARMACEUTICALS HOLDIN

Tonix CFO buys stock at $10.91, signaling confidence in its CNS drug pipeline—especially fibromyalgia and PTSD—despite low market valuation and high volatility. Click to learn insider insight.

Tonix Pharmaceuticals insider buying signals CEO confidence amid tough market: coverage expands for TONMYA®, but cash flow remains flat and earnings negative. Read the analysis.